Neuraptive Therapeutics begins patient enrollment in NTX-001 facial paralysis trial

Neuraptive Therapeutics begins patient enrollment in NTX-001 facial paralysis trial

Neuraptive Therapeutics said that it has enrolled the first patient in its phase 2a clinical trial of NTX-001 for the treatment and prevention of facial paralysis needing surgical repair. The mid-stage facial paralysis prevention study will assess the safety and efficacy of NTX-001 in peripheral nerve injuries caused by trauma in comparison to the standard […]

ATAI Life Sciences partners with Neuronasal to develop concussion treatment

ATAI Life Sciences partners with Neuronasal to develop concussion treatment

ATAI Life Sciences, a German biotech company focused on developing drugs for mental illnesses, has partnered with Neuronasal to develop a short-term treatment for mild traumatic brain injury (mTBI) or concussion. Neuronasal’s concussion treatment includes the intranasal delivery of low doses of N-acetylcysteine (NAC) to patients with acute concussion. N-acetylcysteine has been safely used for […]